Shafique Virani - Feb 1, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Chief Business Officer
Signature: /s/ Nathan Hatfield, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Feb 1, 2023
Transactions value $: -$25,599
Form type: 4
Date filed: 2/3/2023, 04:12 PM
Previous filing: Jan 19, 2023
Next filing: Feb 17, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+106K	+140.27%	$0.00	182K	Feb 1, 2023	Direct	F1, F2
transaction	RXRX	Class A Common Stock	Award	$0	+10.8K	+5.95%	$0.00	193K	Feb 1, 2023	Direct	F3
transaction	RXRX	Class A Common Stock	Tax liability	-$25.6K	-2.99K	-1.55%	$8.55	190K	Feb 1, 2023	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+213K		$0.00	213K	Feb 1, 2023	Class A Common Stock	213K	$8.55	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						637K	Feb 1, 2023	Class A Common Stock	0	$2.22	Direct	F6
holding	RXRX	Stock Option (Right to Buy)						80.5K	Feb 1, 2023	Class A Common Stock	0	$11.40	Direct	F7
holding	RXRX	Stock Option (Right to Buy)						5.44K	Feb 1, 2023	Class A Common Stock	0	$11.40	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2023 and every three months thereafter.
F2	Includes 2,590 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2022.
F3	This RSU vested immediately upon the grant date.
F4	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F5	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F7	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.